Creating new antibody treatments for cancer
Development of Novel Antibody Conjugates for Cancer Immunotherapy
This study is exploring a new way to help cancer patients by creating special treatments that can find and break down certain proteins linked to cancer, which could make existing therapies work better for different types of tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11045678 on NIH RePORTER |
What this research studies
This research focuses on developing innovative antibody conjugates that can target and degrade specific proteins associated with cancer. By using a novel approach called LYTAC, the study aims to enhance the effectiveness of cancer immunotherapy by directing extracellular proteins to the lysosome for degradation. This method could potentially improve the treatment of various cancers by targeting proteins that are currently difficult to address with existing therapies. Patients may benefit from more effective cancer treatments that specifically target their tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that express specific extracellular proteins targeted by the novel antibody conjugates.
Not a fit: Patients with cancers that do not express the targeted extracellular proteins may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade harmful proteins in tumors.
How similar studies have performed: Other research has shown promise with similar approaches, particularly with PROTACs, indicating a potential for success with this novel method.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Tang, Weiping — University of Wisconsin-Madison
- Study coordinator: Tang, Weiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.